Table 2.
Regression Rates after Follow-up between 2010 and 2016, According to Age Group and Cytology Diagnosis
| Mean Time (in months) |
SE (95% CI) | Univariate HR Crude (95%CI) |
p-Value | Bivariate aHR (95%CI) |
p-value | |
|---|---|---|---|---|---|---|
| Age in years | ||||||
| <25 | 12.4 | 0.7 (11.1 - 13.8) | 1.0 (0.9 - 1.2) | 0.36 | 1.4 (1.2 - 1.7) | < 0.01 |
| 25-65 | 13.5 | 0.3 (12.9 - 14.1) | (ref) | (ref) | ||
| >65 | 11.4 | 1.3 (8.8 - 14.0) | 1.2 (0.9 - 1.5) | 0.13 | 0.8 (0.6 - 1.1) | 0.18 |
| Pap Cytology2 | ||||||
| ASC | 13.1 | 0.3 (12.5 - 13.7) | (ref) | (ref) | ||
| LSIL | 14.6 | 0.8 (13.0 - 16.3) | 0.8 (0.7 - 1.0) | 0.06 | 1.0 (0.8 - 1.2) | 0.87 |
| HSIL | 15.1 | 2.5 (10.0 - 20.2) | 0.9 (0.6 - 1.2) | 0.61 | 0.9 (0.7 - 1.2) | 0.68 |
| AGC | 13.3 | 1.6 (9.9 - 16.6) | 1.0 (0.8 - 1.3) | 0.75 | 0.9 (0.6 - 1.4) | 0.83 |
ASC, atypical squamous cells; LSIL, low-grade squamous intraepithelial lesions; HSIL, high-grade squamous intraepithelial lesions; AGC, atypical glandular cells. SD, standard deviations; SE, standard error; CI, confidence interval; HR, hazard ratio; aHR, Hazard ratio adjusted of age; Ref, Reference variable; 1, ASR, Age-standardized incidence rate per 100.000 person-months. All person-months observation (regression event): 19.859; 2, Only pre-malignant cervical lesions.